Happy Flower

Search documents
Tilray(TLRY) - 2026 Q1 - Earnings Call Transcript
2025-10-09 14:00
Tilray Brands (NasdaqGS:TLRY) Q1 2026 Earnings Call October 09, 2025 09:00 AM ET Speaker0Thank you for joining today's conference call to discuss Tilray Brands Financial Results for the First Quarter Fiscal Year twenty twenty six ended 08/31/2025. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session for analysts conducted via audio. I'll now turn the call over to Ms. Barron Narada, Tilray Brands' Chief Corporate Officer. ...
Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane's and Happy Flower Brands
GlobeNewswire News Room· 2025-08-12 11:00
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane's and Happy Flower. Fizzy Jane's, the sparkling seltzer line that debuted this spring in Georgia, North Carolina, and South Carolina, is now available in a 10mg HDD9 THC format, enhancing the buzz while keeping the same crisp, fruit-forward refreshment fans love ...
Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands
Globenewswire· 2025-08-12 11:00
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane's and Happy Flower. Fizzy Jane's, the sparkling seltzer line that debuted this spring in Georgia, North Carolina, and South Carolina, is now available in a 10mg HDD9 THC format, enhancing the buzz while keeping the same crisp, fruit-forward refreshment fans love ...
Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?
ZACKS· 2025-08-01 13:15
Core Insights - Tilray Brands reported its fourth-quarter results for fiscal 2025, with earnings exceeding estimates but sales falling short, both declining compared to the previous year [1][10] - Adjusted EPS was 2 cents, down 50% year over year, while revenues decreased by 2% to $224.5 million, primarily due to weak performance in cannabis and beverages [2] - The company expects adjusted EBITDA for fiscal 2026 to be between $62 million and $72 million, indicating a growth of 13-31% over the prior year [3] Financial Performance - Fiscal 2025 revenues reached $821 million, a 4% increase year over year, largely driven by non-cannabis business diversification [4] - Non-cannabis segments accounted for approximately 70% of total sales, with beverages contributing 29%, distribution 33%, and wellness 8% [5] - Beverage sales rose 19% year over year to $240.6 million, despite SKU rationalization efforts [6] Market Position and Strategy - Tilray has established a strong presence in the hemp market, holding nearly 60% branded market share in the U.S. and 80% in Canada [7] - The company is focusing on enhancing its global supply chain and cultivation footprint to meet growing demand, with expectations of benefiting from Project 420 in the second half of fiscal 2026 [8] - The cannabis segment saw a 9% decline in revenues to $249 million, with international cannabis sales growing 19%, although still a small portion of total cannabis sales [11] Competitive Landscape - Tilray faces intense competition from peers like Aurora Cannabis, Canopy Growth, and Curaleaf Holdings, all pursuing international expansion and cost optimization [12] - The company's stock has dropped 56% year to date, contrasting with a 6% growth in the industry, reflecting ongoing financial challenges and uncertainty around U.S. marijuana legalization [13] Investment Considerations - While Tilray's diversification into craft beverages and THC drinks shows strategic foresight, the decline in its core cannabis business and competitive pressures remain significant near-term challenges [15]